Receptors, Progesterone
"Receptors, Progesterone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
Descriptor ID |
D011980
|
MeSH Number(s) |
D12.776.826.750.765
|
Concept/Terms |
Receptors, Progesterone- Receptors, Progesterone
- Progesterone Receptor
- Receptor, Progesterone
- Progestin Receptors
- Receptors, Progestin
- Progesterone Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Progesterone".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Progesterone".
This graph shows the total number of publications written about "Receptors, Progesterone" by people in this website by year, and whether "Receptors, Progesterone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 3 | 2 | 5 | 1995 | 2 | 1 | 3 | 1996 | 2 | 0 | 2 | 1997 | 4 | 0 | 4 | 1998 | 4 | 2 | 6 | 1999 | 1 | 1 | 2 | 2000 | 3 | 1 | 4 | 2001 | 3 | 0 | 3 | 2002 | 2 | 2 | 4 | 2003 | 5 | 2 | 7 | 2004 | 3 | 0 | 3 | 2005 | 3 | 3 | 6 | 2006 | 5 | 3 | 8 | 2007 | 4 | 4 | 8 | 2008 | 4 | 1 | 5 | 2009 | 4 | 1 | 5 | 2010 | 2 | 5 | 7 | 2011 | 5 | 4 | 9 | 2012 | 9 | 7 | 16 | 2013 | 3 | 5 | 8 | 2014 | 3 | 3 | 6 | 2015 | 3 | 5 | 8 | 2016 | 3 | 2 | 5 | 2017 | 2 | 4 | 6 | 2018 | 1 | 2 | 3 | 2019 | 2 | 0 | 2 | 2020 | 3 | 7 | 10 | 2021 | 3 | 2 | 5 | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Progesterone" by people in Profiles.
-
Liang J, Ingalla ER, Yao X, Wang BE, Tai L, Giltnane J, Liang Y, Daemen A, Moore HM, Aimi J, Chang CW, Gates MR, Eng-Wong J, Tam L, Bacarro N, Roose-Girma M, Bellet M, Hafner M, Metcalfe C. Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer. Sci Transl Med. 2022 Sep 21; 14(663):eabo5959.
-
Borges VF. Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When? J Clin Oncol. 2021 12 10; 39(35):3890-3896.
-
Guzm?n-Arocho YD, Rosenberg SM, Garber JE, Vardeh H, Poorvu PD, Ruddy KJ, Kirkner G, Snow C, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Marotti JD, Warner E, Partridge AH, Collins LC. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer. 2022 02; 126(2):302-309.
-
Cole SE, John EM, Hines LM, Phipps AI, Koo J, Ingles SA, Baumgartner KB, Slattery ML, McKean-Cowden R, Wu AH. Cumulative menstrual months and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities Study. Int J Cancer. 2022 01 15; 150(2):208-220.
-
Mirkin S, Simon JA, Liu JH, Archer DF, Castro PD, Graham S, Bernick B, Komm B. Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert. Menopause. 2021 05 28; 28(9):998-1003.
-
Lim B, Potter DA, Salkeni MA, Silverman P, Haddad TC, Forget F, Awada A, Canon JL, Danso M, Lortholary A, Bourgeois H, Tan-Chiu E, Vincent S, Bahamon B, Galinsky KJ, Patel C, Neuwirth R, Leonard EJ, Diamond JR. Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer. Clin Cancer Res. 2021 06 15; 27(12):3329-3338.
-
Comasco E, Kopp Kallner H, Bixo M, Hirschberg AL, Nyback S, de Grauw H, Epperson CN, Sundstr?m-Poromaa I. Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial. Am J Psychiatry. 2021 03 01; 178(3):256-265.
-
Pak LM, Gaither R, Rosenberg SM, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Snow C, Collins LC, King TA, Partridge AH. Tumor phenotype and concordance in synchronous bilateral breast cancer in young women. Breast Cancer Res Treat. 2021 Apr; 186(3):815-821.
-
Dwyer AR, Truong TH, Kerkvliet CP, Paul KV, Kabos P, Sartorius CA, Lange CA. Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer. Br J Cancer. 2021 01; 124(1):217-227.
-
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto W, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, Yu J, Chiang V, Nakano T, Aoyama H, Mehta MP. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro Oncol. 2020 09 29; 22(9):1359-1367.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|